Re-Irradiation of Locoregional NSCLC Recurrence Using Robotic Stereotactic Body Radiotherapy
| Autor: | Cemile Ceylan, Kayihan Engin, Kezban Berberoglu, Hande Bas Ayata, Metin Güden, Ayhan Kiliç, Andaç Hamacı |
|---|---|
| Přispěvatelé: | Ceylan, C., Hamacl, A., Ayata, H., Berberoglu, K., Klllç, A., Güden, M., Engin, K., Yeditepe Üniversitesi |
| Rok vydání: | 2017 |
| Předmět: |
Male
Oncology Re-Irradiation Cancer Research medicine.medical_specialty Lung Neoplasms Turkey medicine.medical_treatment Radiosurgery 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Risk Factors Recurrence Carcinoma Non-Small-Cell Lung Internal medicine Prevalence Carcinoma medicine Humans In patient Radiation Injuries Lung cancer Survival rate Aged Retrospective Studies Aged 80 and over business.industry Dose-Response Relationship Radiation Radiotherapy Dosage Robotics Hematology Middle Aged medicine.disease Radiotherapy Computer-Assisted Survival Rate Radiation therapy Treatment Outcome 030220 oncology & carcinogenesis Female Re-irradiation Radiology Neoplasm Recurrence Local business Stereotactic body radiotherapy |
| Zdroj: | Oncology Research and Treatment. 40:207-214 |
| ISSN: | 2296-5262 2296-5270 |
| Popis: | Background: We evaluated the efficacy, toxicity, and dose responses of re-irradiation with stereotactic body radiotherapy (SBRT) in patients with recurrent non- small cell lung cancer (NSCLC) after previous irradiation. Patients and Methods: 28 patients were included. Previous median radiation doses were 54 and 66 Gy. The median interval time between previous radiotherapy and SBRT was 14 months. The median follow-up time after SBRT was 9 months (range 3-93 months). To evaluate the effectiveness of SBRT, local control, overall survival, and treatment-related toxicity were reported. Results: SBRT doses and fractionation ranged from 60 to 30 Gy and from 3 to 8, respectively, according to previous doses, location of the recurrence, and interval time. 65% of tumor recurrences overlapped with previous treatment, while 35% of tumors recurred outside of the previous treatment. 4 patients had local progression after SBRT at their first follow-up. The Kaplan-Meier estimates of the 1- and 2-year actuarial overall survival were 71 and 42%, respectively. The mean survival following SBRT was 32.8 months, and the median survival was 21 months. No grade 3 or higher toxicities were observed. Conclusion: Robotic SBRT is a tolerable treatment option with manageable toxicity which can be used with radical or palliative intent in carefully selected patients with locally recurrent tumors after previous irradiation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|